Noted Yale Professor, Thomas Lentz, Joins NanoViricides Scientific Advisory Board (Business Wire)

Wednesday June 25, 7:00 am ET Expert in Virus-Cell Interactions had Proposed Blocking them as a Possible Treatment WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB ), (the “Company”) said that noted Yale University School of Medicine research physician, Thomas Lentz, MD, has agreed to join the NanoViricides’ Scientific Advisory Board (SAB). In accepting the invitation, Dr. Lentz commented by email, “As you know, I was an early proponent of the possibility of treating viral infections by blocking the virus-receptor interaction. While most attempts at putting this into practice have not been successful, I believe the innovative approach employed by NanoViricides has great potential.” Professor Lentz’s research has laid the early foundations for developing anti-viral therapies by blocking virus-cell... [read full story]